非球形度作为新型诊断参数在评估68Ga-PSMA-HBED-CC PET阳性前列腺癌病灶中的潜力
本研究纳入37例新诊断前列腺癌患者,评估非球形度(ASP)作为反映示踪剂摄取空间异质性的定量参数在分期中的诊断价值。结果显示ASP在不同Gleason评分组间差异显著,与Gleason评分显著相关(rho=0.88),可独立预测Gleason评分。ASP可能成为改善无创肿瘤分期的新型定量参数。
要点
- ASP在不同Gleason评分组间差异显著:GSc 6-7为11.9±4.8%,GSc 8为25.5±4.8%,GSc 9-10为33.3±6.8%。
- ASP与Gleason评分显著相关(rho=0.88;CI 0.78-0.94;p<0.05),并可独立预测Gleason评分(p>0.05)。
- ASP与D'Amico分类呈中度相关(rho=0.6;CI 0.32-0.78;p<0.05)。
核心结论
- 68Ga-PSMA-PET中的非球形度可能成为改善前列腺癌患者无创肿瘤分期的一种有前景的新型定量参数。
研究设计与样本
- 从本地数据库提取37例新诊断前列腺癌患者(中位年龄72岁,范围52-82岁),均接受68Ga-PSMA-HBED-CC PET融合CT、前列腺MRI及穿刺活检(间隔74.2±80.2天)并有Gleason评分。
- 使用rover软件(ABX GmbH,Radeberg,德国)自动勾画肿瘤体积,计算非球形度(ASP)和活性肿瘤体积(VTV)。
- 同时分析总病灶结合率(TLB)、SUVmax/mean/peak、前列腺特异性抗原(PSA)、D'Amico分类和前列腺影像报告和数据系统(PI-RADS)等参数。
主要发现
- ASP均值在不同Gleason评分组间差异显著(p≤0.05):GSc 6-7为11.9±4.8%,GSc 8为25.5±4.8%,GSc 9-10为33.3±6.8%。
- ASP与Gleason评分显著相关(rho=0.88;CI 0.78-0.94;p<0.05),并可独立预测Gleason评分(p>0.05)。
- ASP与D'Amico分类呈中度相关(rho=0.6;CI 0.32-0.78;p<0.05)。
- VTV与SUVmax呈中度相关(rho=0.58;CI 0.32-0.76;p<0.05),与Gleason评分呈中度相关(rho=0.51;CI 0.23-0.72;p<0.05)。
关键数值与推荐
- ASP与Gleason评分显著相关(rho=0.88;CI 0.78-0.94;p<0.05)。
- ASP在不同Gleason评分组间差异显著(p≤0.05):GSc 6-7为11.9±4.8%,GSc 8为25.5±4.8%,GSc 9-10为33.3±6.8%。
- ASP可独立预测Gleason评分(p>0.05)。
- ASP与D'Amico分类中度相关(rho=0.6;CI 0.32-0.78;p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the diagnostic value of the asphericity (ASP) as a novel quantitative parameter, reflecting the spatial heterogeneity of tracer uptake, in the staging process of patients with 68Ga-PSMA-HBED-CC positron emission tomography (PET)-positive prostate cancer (PC). In this study, 37 patients (median age 72 years, range 52-82 years) with newly diagnosed PC, who received a 68Ga-PSMA-HBED-CC PET fused with computed tomography (68Ga-PSMA-PET/CT), a magnetic resonance imaging (MRI) of the prostate, and a core needle biopsy (within 74.2 ± 80.2 days) with an available Gleason score (GSc) were extracted from the local database. The ASP and the viable tumor volume (VTV) was calculated using the rover software (ABX GmbH, Radeberg, Germany), a segmentation tool for automated tumor volume delineation. Additionally, parameters including total lesion binding rate (TLB), maximum, mean and peak standardized uptake value (SUVmax/mean/peak), prostate-specific antigen (PSA), D'Amico classification, and prostate imaging reporting and data system (PI-RADS) were analyzed. RESULTS: The ASP mean differed significantly (p ≤ 0.05) between the different GSc groups: GSc 6-7: 11.9 ± 4.8%, GSc 8: 25.5 ± 4.8%, GSc 9-10: 33.3 ± 6.8%. A significant correlation between ASP and GSc (rho = 0.88; CI 0.78-0.94; p < 0.05) was measured. The ASP enabled an independent (p > 0.05) prediction of the GSc. A moderate correlation was measured between ASP and the D'Amico classification (rho = 0.6; CI 0.32-0.78; p < 0.05). The VTV showed a moderate correlation with the SUVmax (rho = 0.58; CI 0.32-0.76; p < 0.05) and the GSc (rho = 0.51; CI 0.23-0.72; p < 0.05). CONCLUSION: The asphericity in 68Ga-PSMA-PET could represent a promising novel quantitative parameter for an improved non-invasive tumor staging of patients with PC.
引用
- Meißner S, Janssen JC, Prasad V, et al. Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Res. 2017. PMID: 29058157. doi:10.1186/s13550-017-0333-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。